Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung
BioNTech Manufacturing GmbH
Endometrial cancer
1 trial -
PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB
BioNTech Manufacturing GmbH
Non-small cell lung cancer
1 trial -
PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo
BioNTech Manufacturing GmbH
First line triple-negative breast cancer (TNBC)
1 trial -
PEMBROLIZUMAB , BNT113
BioNTech Manufacturing GmbH
Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE
BioNTech Manufacturing GmbH
English First-line extensive-stage small-cell lung cancer (ES-SCLC)
1 trial -
BNT111, LIBTAYO 350 mg concentrate for solution for infusion.
BioNTech Manufacturing GmbH
Melanoma (Stage III and IV)
1 trial -
BNT142
BioNTech Manufacturing GmbH
Solid Tumors
1 trial -
BNT327 1-15, BNT327, BNT326
BioNTech Manufacturing GmbH
Advanced solid tumors
1 trial -
BNT327, BNT314, BNT327 1-15
BioNTech Manufacturing GmbH
Metastatic colorectal cancer
1 trial -
BNT327, BNT323
BioNTech Manufacturing GmbH
Advanced Breast Cancer Metastatic Breast Cancer
1 trial -
BNT327, BNT324
BioNTech Manufacturing GmbH
Advanced Lung Cancer
1 trial -
BNT327, DOCETAXEL
BioNTech Manufacturing GmbH
Non-small Cell Lung Cancer
1 trial -
BNT329
BioNTech Manufacturing GmbH
Advanced Solid Cancers
1 trial -
Calciumfolinat HEXAL 10 mg/ml Injektionslösung, Irinotecan HCl AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BNT321, FLUOROURACIL, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung
BioNTech Manufacturing GmbH
Resected (R0 or R1) pancreatic ductal adenocarcinoma
1 trial -
PACLITAXEL , BNT326, CARBOPLATIN , BNT327, PEMBROLIZUMAB , PEMETREXED
BioNTech Manufacturing GmbH
Non-small Cell Lung Cancer
1 trial -
Watchful waiting, RO7198457 (autogene cevumeran)
BioNTech Manufacturing GmbH
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer
1 trial -
A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV
BioNTech Manufacturing GmbH
HIV-1 infection
1 trial -
An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma
BioNTech Manufacturing GmbH
Metastatic melanoma
1 trial -
BNT211, BNT211, BNT211, BNT211
BioNTech Manufacturing GmbH
Solid Tumors
1 trial -
BNT314
BioNTech Manufacturing GmbH
Advanced or metastatic malignant solid tumors
1 trial -
Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
BioNTech Manufacturing GmbH
Advanced non-small cell lung cancer
1 trial -
Dose escalation trial of BNT152+153 in patients with cancer
BioNTech Manufacturing GmbH
Various solid tumors that are metastatic or unresectable
1 trial -
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers
BioNTech Manufacturing GmbH
Tuberculosis
1 trial -
Pfizer-BioNTech mRNA COVID-19 vaccine
BRIGHT MINDS BIOSCIENCES INC.
COVID -19
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources